Neuroone Med Technologies Corp Stock Price, News & Analysis

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) will host a conference call on February 14, 2022, at 4:30 PM Eastern Time to discuss its first-quarter fiscal results for 2022, which ended on December 31, 2021. This call is part of the company’s commitment to improving surgical care for patients with neurological disorders. Interested parties can access the call via toll-free numbers or the provided webcast link.

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) has appointed Chad Wilhelmy as Vice President of Quality Control and Regulatory Affairs. With 20 years of experience in the medical device industry, Wilhelmy aims to enhance the company's quality systems and regulatory foundations. As part of his employment, he received an option to purchase 50,000 shares at an exercise price of $1.95 per share. CEO Dave Rosa expressed confidence in Wilhelmy's experience to support the company's growth, focusing on improving surgical care for neurological disorders.

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) is featured on The Medical Alley Podcast, highlighting their innovations in neurological care. CEO Dave Rosa discusses the company's development of high-definition film electrodes aimed at treating conditions like epilepsy. The podcast aims to enhance public awareness about NeuroOne's commitment to improving surgical options and outcomes for patients with neurological disorders.

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) reported its fourth quarter and full fiscal year 2021 financial results. The Company achieved product revenues of $48,000 and $178,000 for the quarter and year, respectively, compared to no product revenue in the prior year. Notably, collaboration revenue declined significantly to $5,000 for Q4 and $65,000 for the full year from $1.9 million in FY 2020. Operating expenses totaled $10.2 million for the year, resulting in a net loss of $9.9 million. The Company closed a public offering, raising $13.35 million to support product launches.

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) will host a conference call on December 15, 2021, at 9:00 AM Eastern Time to discuss its financial results for the fourth quarter and fiscal year ended September 30, 2021. Interested participants can call 888-506-0062 (toll-free) or 973-528-0011 (international) with access code 527216. The call can also be accessed through a webcast, with replay available post-event.

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced a public offering of 3,750,000 shares of common stock priced at $3.20 per share. The offering is expected to yield approximately $12.0 million in gross proceeds before expenses and is scheduled to close by October 15, 2021. The company has granted underwriters a 30-day option to purchase an additional 562,500 shares. Proceeds will be utilized for working capital and general corporate purposes. The offering is made under the effective shelf registration statement filed with the SEC.

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced a proposed underwritten public offering of its common stock, intending to use the net proceeds for working capital and general corporate purposes. The offering includes a 30-day option for the underwriter to purchase an additional 15% of the shares sold. The offering is subject to market conditions and may not be completed as planned. Craig-Hallum Capital Group acts as the sole underwriter. The public offering is made under an effective shelf registration statement as filed with the SEC on June 14, 2021.

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced the successful completion of an animal feasibility study for its Evo® ablation electrode, conducted at T3 Labs and Georgia Tech under Dr. Robert Gross. The study demonstrated the ability to record brain activity and ablate tissue, aimed at improving treatment for neurological disorders. The Evo ablation electrode, pending FDA clearance, could allow dual procedures in one hospital visit, enhancing patient care and reducing costs. The company also noted its partnership with RBC Medical for radiofrequency hardware development.

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference, taking place virtually from September 13-15, 2021. The presentation will be available on-demand starting September 13. Management will also conduct one-on-one investor meetings during the event. NeuroOne focuses on innovative surgical solutions for neurological disorders, having received FDA clearance for its Evo cortical and sEEG electrode technologies. The company aims to improve patient outcomes and reduce costs.